Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors

[1]  Anna Marie Mulligan,et al.  JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer , 2008, Breast Cancer Research and Treatment.

[2]  T. Nielsen,et al.  Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy , 2007, Breast Cancer Research.

[3]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[4]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[5]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[6]  A. Whittemore,et al.  BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays , 2007, The American journal of surgical pathology.

[7]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[8]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[9]  L. Stitt,et al.  Tumorigenesis and Neoplastic Progression Role of the Integrin-Binding Protein Osteopontin in Lymphatic Metastasis of Breast Cancer , 2006 .

[10]  J. Benítez,et al.  Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer , 2006, Breast Cancer Research and Treatment.

[11]  G. Lockwood,et al.  High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. , 2005, Cancer research.

[12]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[13]  D. Ambrosetti,et al.  Mechanisms underlying differential responses to FGF signaling. , 2005, Cytokine & growth factor reviews.

[14]  Peter Devilee,et al.  Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. , 2005, Cancer research.

[15]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[16]  J. Cigudosa,et al.  Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers , 2005, Breast Cancer Research and Treatment.

[17]  S. Ethier,et al.  Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. , 2004, Molecular cancer research : MCR.

[18]  E. Wit.  Design and Analysis of DNA Microarray Investigations , 2004, Human Genomics.

[19]  G. Dontu,et al.  Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells , 2004, Breast Cancer Research.

[20]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[21]  Norman Boyd,et al.  The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.

[22]  L. Wakefield,et al.  The two faces of transforming growth factor β in carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Chambers,et al.  Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways , 2003, Oncogene.

[25]  L. Wakefield,et al.  The two faces of transforming growth factor beta in carcinogenesis. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  L. Belghiti,et al.  Prognostic factors in breast cancer , 2002 .

[27]  A. Whittemore,et al.  Comparison of DNA‐ and RNA‐Based Methods for Detection of Truncating BRCA1 Mutations , 2002, Human mutation.

[28]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[29]  J. Thiery,et al.  Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. , 2002, Development.

[30]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[31]  J. Rossant,et al.  Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  N. Boyd,et al.  The Cooperative Familial Registry for Breast Cancer Studies: design and first year recruitment rates in Ontario. , 2001, Journal of clinical epidemiology.

[34]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[35]  A. Chambers,et al.  Osteopontin‐induced, integrin‐dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met) , 2000, Journal of cellular biochemistry.

[36]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[37]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[38]  G. Brattsand.  Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors , 2000, British Journal of Cancer.

[39]  K. Herzig,et al.  Expression of keratinocyte growth factor and its receptor in colorectal cancer , 2000, European journal of clinical investigation.

[40]  B. Spencer‐Dene,et al.  An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. , 2000, Development.

[41]  S. Abe,et al.  Vascular endothelial growth factor and osteopontin in tumor biology. , 2000, Critical reviews in oncogenesis.

[42]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[43]  J. Peyrat,et al.  Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[45]  I. Bernstein,et al.  The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells. , 1998, Blood.

[46]  K Vajda,et al.  [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.

[47]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[48]  Russ P Carstens,et al.  Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer , 1997, Oncogene.

[49]  J. Hanfelt,et al.  MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice , 1997, Oncogene.

[50]  R. Coombes,et al.  Expression of keratinocyte growth factor and its receptor in human breast cancer. , 1997, British Journal of Cancer.

[51]  H. Moses,et al.  Regulation of differentiation by TFG-β , 1996 .

[52]  F. Bertucci,et al.  Expression of fgf and fgf receptor genes in human breast cancer , 1995, International journal of cancer.

[53]  S. McLeskey,et al.  MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. , 1994, Cancer research.

[54]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.